Article Text

Download PDFPDF
CASE REPORT
Itraconazole as ‘bridge therapy’ to anti-IgE in a patient with severe asthma with fungal sensitisation
  1. Stefano Pizzimenti,
  2. Claudia Bussolino,
  3. Iuliana Badiu,
  4. Giovanni Rolla
  1. Department of Allergy and Clinical Immunology, University of Torino & AO Ordine Mauriziano, Torino, Italy
  1. Correspondence to Professor Giovanni Rolla, grolla{at}mauriziano.it

Summary

Sensitisation to fungi has been reported to play an important role in a particular phenotype of severe asthma, the so-called severe asthma with fungal sensitisation, characterised by high levels of total IgE, which may be an obstacle to anti-IgE therapy. We describe here the case of a polysensitised woman with refractory asthma, sensitised to Aspergillus fumigatus with high total IgE values (1793 kUA/l), but without the diagnostic criteria for allergic bronchopulmonary aspergillosis. Additional therapy with itraconazole leads to the decrease of total IgE to the limits recommended for proper omalizumab dosing (30–1500 kUA/l). Itraconazole, used as bridge therapy, provided us the opportunity to start anti-IgE treatment in a patient with high levels of total IgE, beyond the upper limits recommended for proper prescription of omalizumab.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.